English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Objective:  Clinical studies have shown that trastuzumab combined with pertuzumab (dual-targeted drug therapy) can significantly improve the treatment status and prognosis of HER-2 positive breast cancer patients through double targeting of HER-2. This study systematically evaluated the efficacy and safety of trastuzumab combined with pertuzumab in the treatment of HER-2 positive breast cancer. Method:  We search relevant databases and collect RCTs on the treatment of HER-2 positive breast cancer with dual-targeted treatment. Meta-analysis was performed using Revman5.4 software. Results:  A total of 10 studies for 8553 patients were included. Meta-analysis showed that, in terms of efficacy, overall survival (OS) (HR = 1.40, 95%CI = 1.29–1.53,  p  &lt; 0.00001) and progression-free survival (PFS) (HR = 1.36, 95%CI = 1.28–1.46,  p  &lt; 0.00001) in dual-targeted drug therapy were better than which in the single-targeted drug group. In terms of safety, the highest incidence (Relative risk, RR) of Adverse reactions was Infections and infestations (RR = 1.48, 95%CI = 1.24–1.77,  p  &lt; 0.0001) follow by Nervous system disorders (RR = 1.29, 95%CI = 1.12–1.50,  p  = 0.0006), Gastrointestinal disorders (RR = 1.25, 95%CI = 1.18–1.32,  p  &lt; 0.0001), Respiratory, thoracic, and mediastinal disorders (RR = 1.21, 95%CI = 1.01–1.46,  p  = 0.04), Skin and subcutaneous tissue disorders (RR = 1.14, 95%CI = 1.06–1.22,  p  = 0.0002) and General disorders (RR = 1.14, 95%CI = 1.04–1.25,  p  = 0.004) in dual-targeted drug therapy group. The incidence of Blood system disorder (RR = 0.94, 95%CI = 0.84–1.06,  p  = 0.32) and Liver dysfunction (RR = 0.80, 95%CI = 0.66–0.98,  p  = 0.03) was lower than that of the single targeted drug group. Conclusion:  Dual-targeted treatment for HER-2-positive breast cancer can prolong the OS, PFS and improve the quality of patients’ life. Meanwhile, it also brings a higher medication risk, which requires a rational selection of drug symptomatic interventions.

Evaluation of HER-2 positive breast cancer treated with dual-targeted treatment of trastuzumab plus pertuzumab